Loading
Used as first treatment, dabrafenib plus trametinib shrank tumours in almost two thirds of patients with BRAF V600E-mutant lung cancer and controlled the disease for over a year, supporting its use before chemotherapy.
First-line cohort of the phase 2 multicohort study: 36 patients with untreated BRAF V600E-mutant metastatic non-small-cell lung cancer received dabrafenib plus trametinib.
Objective response was 64 percent with a median progression-free survival of 10.9 months and median overall survival of 24.6 months at the initial report; updated analyses showed durable benefit.
BRAF plus MEK inhibition is a standard first-line option for BRAF V600E lung cancer, with chemo-immunotherapy as the alternative or subsequent line.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib, The Lancet Oncology.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.